Knight Therapeutics (GUD) Earnings Date, Estimates & Call Transcripts C$5.65 +0.01 (+0.18%) (As of 11/1/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Knight Therapeutics Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 7Before Market OpensConfirmedActual EPS (Aug. 8) -C$0.02 Missed By -C$0.05 Consensus EPS (Aug. 8) C$0.03 Knight Therapeutics posted Q2 2024 earnings on August 8, 2024, reporting an EPS of -C$0.02, which missed the consensus estimate of C$0.03 by C$0.05. Quarterly revenue was reported to be C$95.57 million, above the consensus estimate of C$89.83 million. With a trailing EPS of -C$0.20, GUD Upcoming EarningsKnight Therapeutics' next earnings date is scheduled for Thursday, November 7, 2024. Get Knight Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Knight Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataGUD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GUD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade Knight Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-C$0.01-C$0.01-C$0.01Q2 20241C$0.01C$0.01C$0.01Q3 20242-C$0.01C$0.06C$0.03Q4 20241C$0.00C$0.00C$0.00FY 20245-C$0.01C$0.06C$0.03Q1 20251C$0.00C$0.00C$0.00Q2 20251C$0.01C$0.01C$0.01Q3 20251C$0.01C$0.01C$0.01Q4 20251C$0.01C$0.01C$0.01FY 20254C$0.03C$0.03C$0.03 Knight Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/7/2024(Confirmed)------- 8/8/2024Q2 2024C$0.03C-$0.02 -C$0.05C-$0.02C$89.83MC$95.57M5/9/2024Q1 2024C$0.02C-$0.04 -C$0.06C-$0.04C$80.27MC$86.60M3/21/2024Q4 2023C$0.02C-$0.03 -C$0.05C$0.17C$78.37MC$74.20M11/9/2023Q3 2023C$0.03C$0.09+C$0.06C$0.09C$72.00MC$81.50M8/10/2023Q2 2023C$0.03C$0.02 -C$0.01C$0.02C$80.15MC$89.91M5/11/2023Q1 2023-C-$0.04 -C$0.04C-$0.04C$74.80MC$82.60M Get the Latest News and Ratings for GUD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/23/2023Q4 2022-C$0.02+C$0.02C$0.17C$62.00MC$81.66M11/10/2022Q3 2022C-$0.01C$0.02+C$0.03C$0.03C$67.03MC$72.28M ` More Earnings Resources from MarketBeat Related Companies Aurora Cannabis Earnings Date Cipher Pharmaceuticals Earnings Date Organigram Earnings Date BioSyent Earnings Date HLS Therapeutics Earnings Date Medexus Pharmaceuticals Earnings Date Decibel Cannabis Earnings Date Medicure Earnings Date Valeo Pharma Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade This page (TSE:GUD) was last updated on 11/3/2024 by MarketBeat.com Staff From Our PartnersThe Death Knell for U.S. StocksThey are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "Th...InvestorPlace | SponsoredCharles Payne Wants You Prepared for Q4Charles Payne Wants You Prepared for Q4 Because as we look toward 2025, there's no denying that market vola...Unstoppable Prosperity | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.